Adage Capital Partners
TERN

Adage Capital Partners’s Terns Pharmaceuticals TERN Stock Holding History

Adage Capital Partners’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,124,817
Closed -$112M – 1087
2026
Q1 		$112M Sell
2,124,817
-3,425,183
-62% -$141M 0.17% 118
2025
Q4 		$224M Buy
5,550,000
+1,611,000
+41% +$37.2M 0.34% 47
2025
Q3 		$29.6M Buy
3,939,000
+2,659,000
+208% +$17M 0.05% 365
2025
Q2 		$4.77M Buy
+1,280,000
New +$4M 0.01% 708
2024
Q3 		– Sell
-975,000
Closed -$6.64M – 936
2024
Q2 		$6.64M Buy
975,000
+125,000
+15% +$757K 0.01% 673
2024
Q1 		$5.58M Sell
850,000
-200,000
-19% -$1.31M 0.01% 685
2023
Q4 		$6.81M Buy
1,050,000
+950,000
+950% +$5.02M 0.01% 653
2023
Q3 		$503K Sell
100,000
-50,000
-33% -$317K ﹤0.01% 781
2023
Q2 		$1.31M Buy
+150,000
New +$1.75M ﹤0.01% 759

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Adage Capital Partners's TERN Position: Q2 2026 in Review

Adage Capital Partners sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 2,124,817 shares — an estimated $112M sold.

Adage Capital Partners first reported a position in TERN in Q2 2023 and held it in 9 quarters. The position peaked at $224M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Adage Capital Partners reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Adage Capital Partners sold 2,124,817 Terns Pharmaceuticals shares in Q2 2026, an estimated $112M.
  • Adage Capital Partners first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 9 quarters.
  • Adage Capital Partners's Terns Pharmaceuticals position peaked at $224M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.